Assessing the use of activated protein c in the treatment of severe sepsis.

被引：97
|
作者：
Siegel, JP [1 ]
机构：
[1] Ctr Biol Evaluat & Res, Rockville, MD 20852 USA
来源：
NEW ENGLAND JOURNAL OF MEDICINE | 2002年 / 347卷 / 13期
关键词：
D O I：
10.1056/NEJMsb021512
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：1030 / 1034
页数：6
相关论文
共 50 条
  • [1] Activated protein C for severe sepsis.
    Ely, EW
    Bernard, GR
    Vincent, J
    NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (13): : 1035 - 1036
  • [2] An economic evaluation of activated protein C treatment for severe sepsis.
    Manns, BJ
    Lee, H
    Doig, CJ
    Johnson, D
    Donaldson, C
    NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (13): : 993 - 1000
  • [3] Risks and benefits of activated protein C treatment for severe sepsis.
    Warren, HS
    Suffredini, AF
    Eichacker, PQ
    Munford, RS
    NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (13): : 1027 - 1030
  • [4] Mechanisms for mortality reduction by activated protein C in severe sepsis.
    Kerschen, Edward J.
    Cooley, Brian C.
    Castellino, Francis J.
    Coughlin, Shaun R.
    Fernandez, Jose A.
    Griffin, John H.
    Weiler, Hartmut
    BLOOD, 2006, 108 (11) : 5A - 5A
  • [5] Efficacy and safety of recombinant human activated protein C for severe sepsis.
    Bernard, GR
    Vincent, JL
    Laterre, P
    LaRosa, SP
    Dhainaut, JF
    Lopez-Rodriguez, A
    Steingrub, JS
    Garber, GE
    Helterbrand, JD
    Ely, EW
    Fisher, CJ
    NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (10): : 699 - 709
  • [6] Drotrecogin alfa (activated): implementing institutional guidelines for use and assessing treatment outcomes in patients with severe sepsis.
    Clarke, H
    Barlows, TG
    Machado, C
    Dalin, G
    Prager, R
    PHARMACOTHERAPY, 2002, 22 (10): : 1374 - 1375
  • [7] Activated protein C for the treatment of severe sepsis
    Houston, G.
    Cuthbertson, B. H.
    CLINICAL MICROBIOLOGY AND INFECTION, 2009, 15 (04) : 319 - 324
  • [8] Recombinant human activated protein C for use in severe sepsis
    Bearden, DT
    Garvin, CG
    ANNALS OF PHARMACOTHERAPY, 2002, 36 (09) : 1424 - 1429
  • [9] THE INFLUENCE OF DRG FINANCING ON THE USAGE OF ACTIVATED PROTEIN C IN SEPSIS.
    Varga, Szilard
    Mikor, Andras
    Boncz, Imre
    CRITICAL CARE MEDICINE, 2008, 36 (12) : A22 - A22
  • [10] Dysfunction of endothelial protein C activation in severe meningococcal sepsis.
    Faust, SN
    Levin, M
    Harrison, OB
    Goldin, RD
    Lockhart, MS
    Kondaveeti, S
    Laszik, Z
    Esmon, CT
    Heyderman, RS
    NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (06): : 408 - 416
12345